Article

Uncovering obstacles yields strategies for improving adherence

Ophthalmologists need to recognize that there are many obstacles to glaucoma medication adherence before starting a dialogue with patients to identify barriers specific to individuals and strategies for overcoming them, said Robert D. Fechtner, MD, professor of ophthalmology and director, glaucoma division, New Jersey Medical School-UDMNJ, Newark.

Ophthalmologists need to recognize that there are many obstacles to glaucoma medication adherence before starting a dialogue with patients to identify barriers specific to individuals and strategies for overcoming them, said Robert D. Fechtner, MD, professor of ophthalmology and director, glaucoma division, New Jersey Medical School-UDMNJ, Newark.

“Understand that patients won’t always use their glaucoma medications as directed, and they need to be educated that they have the ability to control their disease,” Dr. Fechtner said,

Identifying the individual who is non-adherent can be difficult because medication use may improve immediately before a scheduled visit and IOP will appear to be controlled, he said. Certain strategies can enable detection of patients with adherence problems.

Patients may be asked to name their medication, its appearance, and when it was last refilled. They should be able to tell what times of the day they use their medications and may be asked to demonstrate with a bottle of artificial tears how they instill their drops.

In exploring adherence, physicians also should formulate questions in a framework that gives patients permission to tell the truth.

“Tell the patient you understand there are obstacles to using medications, that most patients have some difficulties and forget a few times a week, and then ask what problems they have and how many times they forgot this week,” Dr. Fechtner explained.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.